SRPT Stock Analysis: Buy, Sell, or Hold?
SRPT - Sarepta Therapeutics,, Inc. Common Stock
$20.34
-0.89 (-4.21%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
24d
Smart Money Accumulation
SRPT is down 3.7% this week, but smart money is accumulating calls. Top strike: $25 2026-03-20 with 482 OI. Call ratio: 67% View Scanner →
Strength: 3.6/10
Get Alerted When SRPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
22 traders called SRPT this week
92% bullish • 3 bearish
92% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SRPT shows positive signals but monitor for confirmation. Market pricing in 3.0% decline. Moderate conviction.
💡 BUY OPPORTUNITY: SRPT shows positive signals but monitor for confirmation. Market pricing in 3.0% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$32.81
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$20.37
0.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SRPT is currently trading at $20.34, which is considered oversold relative to its 30-day fair value range of $20.98 to $22.61. The stock's valuation (Forward PE: 6.8) is in line with its historical norms (7.5). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This pessimistic expectation contrasts with the company's recent 2663.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $20.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $20.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$20.98 -
$22.61
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- NEUTRAL: Near Wall St target ($21.43)
Fair Price Analysis
30-Day Fair Range
$20.98 -
$22.61
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$20.10
Resistance Level
$24.68
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
6.80
Wall Street Target
$21.43
(+0.9%)
Revenue Growth (YoY)
-14.5%
Earnings Growth (YoY)
2663.8%
Profit Margin
-11.2%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
6.8 vs 7.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$20.60
(-3%)
2-Year Target
$19.98
(-6%)
3-Year Target
$19.38
(-9%)
3-Yr Target (if PE normalizes)
(PE: 7→8)
$21.37
(+1%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.8 to 7.5
Stabilization Target:
$23.42
(+10.3%)
PE Expansion Potential:
+10.3%
Last updated: January 31, 2026 9:40 AM ET
Data refreshes hourly during market hours. Next update: 10:40 AM
Data refreshes hourly during market hours. Next update: 10:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$90 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$35 | 51 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$65 | 60 HOLD |
Advanced SRPT Option Strategies
Professional options setups generated by AI based on today's SRPT price and gamma walls.
